Home

Stoke Therapeutics, Inc. - Common Stock (STOK)

8.2600
-0.6100 (-6.88%)

Stoke Therapeutics Inc is a biotechnology company focused on developing innovative therapies to treat genetic diseases by harnessing the power of messenger RNA (mRNA) biology

The company is dedicated to addressing the underlying causes of diseases by enhancing the production of proteins through its proprietary platform, which aims to restore the normal function of genes that are dysfunctional due to genetic mutations. By prioritizing precision medicine, Stoke Therapeutics works towards delivering transformative treatments that can improve the quality of life for patients suffering from various neurological disorders and other serious conditions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close8.870
Open8.950
Bid7.990
Ask8.790
Day's Range8.030 - 8.950
52 Week Range5.600 - 17.58
Volume1,260,606
Market Cap365.00M
PE Ratio (TTM)-3.933
EPS (TTM)-2.1
Dividend & YieldN/A (N/A)
1 Month Average Volume813,289

News & Press Releases

Forecasting The Future: 7 Analyst Projections For Stoke Therapeuticsbenzinga.com
Via Benzinga · March 18, 2025
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the full year ended December 31, 2024 and provided business updates.
By Stoke Therapeutics, Inc. · Via Business Wire · March 18, 2025
Stoke Therapeutics Announces CEO Transition
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome.
By Stoke Therapeutics, Inc. · Via Business Wire · March 18, 2025
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Expertsbenzinga.com
Via Benzinga · January 8, 2025
A Closer Look at 5 Analyst Recommendations For Stoke Therapeuticsbenzinga.com
Via Benzinga · June 28, 2024
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the following upcoming investor conferences:
By Stoke Therapeutics, Inc. · Via Business Wire · February 26, 2025
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Dealbenzinga.com
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
Via Benzinga · February 18, 2025
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome. Stoke recently announced plans to initiate a global Phase 3 registrational study of zorevunersen (EMPEROR) following successful alignment with regulatory agencies in the United States, Europe, and Japan. The study is on track to initiate in the second quarter of 2025, with a pivotal data readout expected in the second half of 2027, which is anticipated to support global regulatory filings.
By Stoke Therapeutics, Inc. · Via Business Wire · February 18, 2025
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights
By Biogen Inc. · Via GlobeNewswire · February 18, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · February 11, 2025
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT).
By Stoke Therapeutics, Inc. · Via Business Wire · January 8, 2025
Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced alignment with global regulatory agencies on the design of the Company’s Phase 3 EMPEROR study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
By Stoke Therapeutics · Via Business Wire · January 7, 2025
Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
By Stoke Therapeutics, Inc. · Via Business Wire · January 6, 2025
Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced new data from an analysis of nine patients treated with an initial 2 or 3 doses of 70mg, followed by 45mg maintenance dosing in the Phase 1/2a and open-label extension (OLE) studies of zorevunersen. Substantial and durable reductions in convulsive seizure frequency were observed in these patients who received zorevunersen on top of the best available anti-seizure medicines. In addition, patients treated in the OLE studies showed continuous improvements in multiple measures of cognition and behavior with ongoing treatment through 2 years. Zorevunersen was generally well tolerated across the studies. Together, these data support the company’s proposed Phase 3 registrational study regimen and its efforts to develop zorevunersen as a disease-modifying medicine for the treatment of Dravet syndrome.
By Stoke Therapeutics, Inc. · Via Business Wire · December 6, 2024
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · December 4, 2024
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene. Zorevunersen is being developed as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
By Stoke Therapeutics, Inc. · Via Business Wire · December 4, 2024
Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced several presentations at the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6 – 10, in Los Angeles, California. In addition, the Company will host a virtual event with discussions led by leading clinicians and patient advocates for investors and research analysts on Monday, December 9 at 8:30 am Eastern (5:30 am Pacific). The Company is advancing zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
By Stoke Therapeutics, Inc. · Via Business Wire · December 2, 2024
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for the third quarter of 2024 and provided business updates including those related to zorevunersen, the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.
By Stoke Therapeutics, Inc. · Via Business Wire · November 5, 2024
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced highlights from presentations at the 15th European Epilepsy Congress (EEC) related to the Company’s work to develop the first disease-modifying medicine for Dravet syndrome. Zorevunersen (STK-001) data showing substantial and sustained reductions in seizures and meaningful improvements in multiple measures of cognition and behavior were presented for the first time in a scientific forum. New data from an analysis of patients treated in the Phase 1/2a ADMIRAL study showed improvements in cognition and behavior during the first year of treatment with additional increases demonstrated as treatment continued. In addition, data from a two-year natural history study presented at the meeting showed that despite treatment with standard-of-care antiseizure medications, patients with Dravet syndrome continued to have high seizure rates and plateaued in their neurodevelopment, resulting in a widening gap in development compared to their neurotypical peers.
By Stoke Therapeutics, Inc. · Via Business Wire · September 10, 2024
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Olson will be responsible for leading and executing the Company’s global corporate strategy and business development.
By Stoke Therapeutics, Inc. · Via Business Wire · September 4, 2024
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the following upcoming investor conferences:
By Stoke Therapeutics, Inc. · Via Business Wire · September 3, 2024
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced it will present data from its Dravet syndrome clinical program at the 15th European Epilepsy Congress (EEC) taking place September 7 – 11, in Rome, Italy.
By Stoke Therapeutics, Inc. · Via Business Wire · September 3, 2024
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that, effective on August 15, 2024, the company granted stock options to purchase an aggregate of 48,400 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Stoke Therapeutics, Inc. · Via Business Wire · August 16, 2024
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today reported financial results for the second quarter of 2024 and provided business updates including those related to zorevunersen (STK-001), the Company’s proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.
By Stoke Therapeutics, Inc. · Via Business Wire · August 7, 2024
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that, effective on July 15, 2024, the company granted stock options to purchase an aggregate of 122,900 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
By Stoke Therapeutics, Inc. · Via Business Wire · July 16, 2024